A phase 3 trial of luspatercept in patients with transfusion-dependent β-thalassemia.
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients with transfusion-dependent β-thalassemia need regular red-cell transfusions. Luspatercept, a recombinant fusion protein that binds to select transforming growth factor β superfamily ligands, may enhance erythroid maturation and reduce the transfusion burden (the total number of red-cell units transfused) in such patients. METHODS: In this randomized, double-blind, phase 3 trial, we assigned, in a 2:1 ratio, adults with transfusion-dependent β-thalassemia to receive best supportive care plus luspatercept (at a dose of 1.00 to 1.25 mg per kilogram of body weight) or placebo for at least 48 weeks. The primary end point was the percentage of patients who had a reduction in the transfusion burden of at least 33% from baseline during weeks 13 through 24 plus a reduction of at least 2 red-cell units over this 12-week interval. Other efficacy end points included reductions in the transfusion burden during any 12-week interval and results of iron studies. RESULTS: A total of 224 patients were assigned to the luspatercept group and 112 to the placebo group. Luspatercept or placebo was administered for a median of approximately 64 weeks in both groups. The percentage of patients who had a reduction in the transfusion burden of at least 33% from baseline during weeks 13 through 24 plus a reduction of at least 2 red-cell units over this 12-week interval was significantly greater in the luspatercept group than in the placebo group (21.4% vs. 4.5%, P<0.001). During any 12-week interval, the percentage of patients who had a reduction in transfusion burden of at least 33% was greater in the luspatercept group than in the placebo group (70.5% vs. 29.5%), as was the percentage of those who had a reduction of at least 50% (40.2% vs. 6.3%). The least-squares mean difference between the groups in serum ferritin levels at week 48 was -348 μg per liter (95% confidence interval, -517 to -179) in favor of luspatercept. Adverse events of transient bone pain, arthralgia, dizziness, hypertension, and hyperuricemia were more common with luspatercept than placebo. CONCLUSIONS: The percentage of patients with transfusion-dependent β-thalassemia who had a reduction in transfusion burden was significantly greater in the luspatercept group than in the placebo group, and few adverse events led to the discontinuation of treatment. (Funded by Celgene and Acceleron Pharma; BELIEVE ClinicalTrials.gov number, NCT02604433; EudraCT number, 2015-003224-31.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recently approved therapies, including luspatercept 9 and crizanlizumab, 10 have reduced transfusion requirements in patients with TDT and the incidence of vaso-occlusive episodes in those with SCD, respectively, but neither treatment addresses the underlying cause of the disease nor fully ameliorates disease manifestations.”
From CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia (2021) · cites this paper as [9]
In the citing paper
“Recently approved therapies, including luspatercept 9 and crizanlizumab, 10 have reduced transfusion requirements in patients with TDT and the incidence of vaso-occlusive episodes in those with SCD, respectively, but neither treatment addresses the underlying cause of the disease nor fully ameliorates disease manifestations.”
From CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia (2021) · cites this paper as [9]
Citations
Cites
Global epidemiology of haemoglobin disorders and derived service indicators
Modell, B. (2008) · Bulletin of the World Health Organization · doi:10.2471/blt.06.036673 · Cited by 1,924
Borgna‐Pignatti, C., Rugolotto, S., Stefano, P. D., Zhao, H., Cappellini, M. D., Vecchio, G. C. D., Romeo, M. A., Forni, G. L., Gamberini, M. R., Ghilardi, R., et al. (2004) · PubMed · Cited by 1,119
Self-citationWood, J. C., Enriquez, C., Ghugre, N., Tyzka, J. M., Carson, S., Nelson, M. D., & Coates, T. D. (2005) · Blood · doi:10.1182/blood-2004-10-3982 · Cited by 1,045
Self-citationNoninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance
St. Pierre, T. G., Clark, P. R., Chua-anusorn, W., Fleming, A. J., Jeffrey, G. P., Olynyk, J. K., Pootrakul, P., Robins, E., & Lindeman, R. (2005) · Blood · doi:10.1182/blood-2004-01-0177 · Cited by 909
The inherited diseases of hemoglobin are an emerging global health burden
Weatherall, D. J. (2010) · Blood · doi:10.1182/blood-2010-01-251348 · Cited by 903
Taher, A. T., Weatherall, D. J., & Cappellini, M. D. (2018) · The Lancet · doi:10.1016/s0140-6736(17)31822-6 · Cited by 807
Self-citationGene Therapy in Patients with Transfusion-Dependent β-Thalassemia
Thompson, A. A., Walters, M. C., Kwiatkowski, J., Rasko, J. E. J., Ribeil, J.-A., Hongeng, S., Magrin, E., Schiller, G. J., Payen, E., Semeraro, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1705342 · Cited by 684
Self-citationSurvival in β-thalassaemia major in the UK: data from the UK Thalassaemia Register
Modell, B., Khan, M., & Darlison, M. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02357-6 · Cited by 583
Suragani, R. N. V. S., Cadena, S. M., Cawley, S. M., Sako, D., Mitchell, D., Li, R., Davies, M. V., Alexander, M. J., Devine, M., Loveday, K. S., et al. (2014) · Nature Medicine · doi:10.1038/nm.3512 · Cited by 445
Taher, A. T., Musallam, K. M., Karimi, M., El-Beshlawy, A., Belhoul, K., Daar, S., Saned, M.-S., El-Chafic, A.-H., Fasulo, M. R., & Cappellini, M. D. (2010) · Blood · doi:10.1182/blood-2009-09-243154 · Cited by 392
Self-citation
Cited by
Items 301–337 of 337
Research Progress of Luspatercept in the Treatment of β-Thalassemia
唐, 彩. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.1592656
Gene Editing with CRISPR: A New Era for Treating Beta Thalassemia
Amematekpo, Y. (2025) · American journal of student research. · doi:10.70251/hyjr2348.35536540
Case Report: Luspatercept for transfusion-dependent anemia of unknown etiology
Chandra, S., Bansal, V., Sharma, P., & Cossor, F. I. (2026) · Frontiers in Hematology · doi:10.3389/frhem.2025.1714544
Modern therapeutic approaches for β-thalassemia: from blood transfusion to gene therapy
Dolgushina, E. N., Коптева, О. С., Shakirova, A. L., Lepik, K. V., Bykova, T. A., Zubarovskaya, L. S., & Kulagin, A. (2026) · Russian Journal of Pediatric Hematology and Oncology · doi:10.21682/2311-1267-2025-12-3-56-67
Niedokrwistość u chorych na mielofibrozę — możliwości terapii
Gołoś, A., & Góra‐Tybor, J. (2025) · Hematologia — Edukacja · doi:10.5603/hemedu.104518
Case series: a rare dominant form of β-thalassemia successfully treated by luspatercept
Allard, P., Kulozik, A. E., & Kunz, J. B. (2026) · Annals of Hematology · doi:10.1007/s00277-026-06778-8
How I manage luspatercept in transfusion‐dependent beta‐thalassemia
Panzieri, D. L., Scaramellini, N., Leoni, S., Taher, A. T., Cappellini, M. D., & Motta, I. (2026) · HemaSphere · doi:10.1002/hem3.70315
Self-citationHYPERCOAGULABILITY AND THROMBOTIC RISK IN BETA-THALASSEMIA: CLINICAL AND LABORATORY INSIGHTS
Stoencheva, S. (2026) · MEDIS – International Journal of Medical Sciences and Research · doi:10.35120/medisij0501033s
Consistency Assessment and Regional Sample Size Calculation for MRCT Under Random Effects Model
Ren, X., & Xu, J. (2026) · Pharmaceutical Statistics · doi:10.1002/pst.70090
“Yet, in many situations such as oncology and cardiovascular trials with long duration, regional treatment heterogeneity arises due to ethnicity reason or regional covariates (e.g., sex or age) shift (Cappellini et al., 2020).”
Cohrt, K. O., & O’Dea, S. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27083384
“…erythroid maturation) and crizanlizumab (a monoclonal antibody that improves the flow of sickled red blood cells through blood vessels) have reduced some symptoms of TDT and SCD, respectively, but neither addresses the root cause of disease nor fully ameliorates all disease manifestations [45,46].”
Zhang, Z., Hu, Q., Wang, L., Yang, C., Chen, M., & Han, B. F. (2026) · BMC Medicine · doi:10.1186/s12916-026-04887-9
“Luspatercept has been reported to be clinically effective in the treatment of anemia for LR-MDS, β-thalassemia, and congenital sideroblastic anemia [12, 13, 21].”
InfluentialThalassemia: Management Issues
Angelucci, E., & Pinto, V. M. (2026) · Springer eBooks · doi:10.1007/978-3-032-13858-3_12
Su, C., Hasebe, M., van der Graaf, A., Yang, Y., Tsao, H. M., Smith, L., Butler‐Laporte, G., Zhou, S., Zhang, W., Lu, T., et al. (2026) · medRxiv · doi:10.64898/2026.05.01.26352257
Pyruvate Kinase Activation in the Management of Thalassemia and Sickle Cell Disease
Musallam, K. M., & Andemariam, B. (2026) · Hemoglobin · doi:10.1080/03630269.2026.2682386 · Cited by 1
Vojjala, N., Nassar, M., Nanjareddy, S., Shah, R., Kotla, N. K., & Singh, V. (2026) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2026.2684311
“It received initial Food and Drug Administration (FDA) approval in 2019 based on the results of the BELIEVE trial in patients with transfusion-dependent beta thalassemia [6].”
InfluentialThalassemia – From Molecular Diagnosis to Innovative Therapies
Bădulescu, O.-V., Ciocoiu, M., Tudor, R. C., Filip, N., Vladeanu, M. C., Bararu‐Bojan, I., Ursanu-Bădulescu, I.-A., Tudor, C., Bojan, A., & Tesoi, D.-F. (2026) · IntechOpen eBooks · doi:10.5772/intechopen.1016193
Outcomes with luspatercept in patients with β-thalassemia: a systematic review and meta-analysis
Babiker, N., Abady, E. M. A., Shahid, H., Rehman, W. U., Babker, F., Sarhan, M. M., Azzazi, H. E., Mohamed, M. A. E., Javed, H. M. H., & Samadi, Y. (2026) · Annals of Hematology · doi:10.1007/s00277-026-07151-5
“Clinical studies have shown that luspatercept significantly reduces transfusion burden and increases hemoglobin concentration [8, 9].”
InfluentialEIF2AK1 As a Key Genetic Determinant of Luspatercept Resistance in Transfusion‐Dependent Thalassemia
Iscaro, A., Leoni, S., Russo, F., Brancaleoni, V., Rosato, B. E., Marra, R., Nostroso, A., Scaramellini, N., Panzieri, D. L., Villa, I., et al. (2026) · American Journal of Hematology · doi:10.1002/ajh.70434
Taher, A. T., Hodroj, M. H., & Cappellini, M. D. (2026) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2026.2700242
“In the phase III BELIEVE trial, luspatercept achieved a ≥33% reduction in transfusion burden during weeks 13–24 in 21.4% of patients compared with 4.5% in the placebo group, establishing its efficacy in transfusion-dependent β-thalassemia [3].”
InfluentialSelf-citationVadivelan, A. A., & Coates, T. D. (2026) · American Journal of Hematology · doi:10.1002/ajh.70439
“Within 3 months of receiving luspater-cept, patient showed a rapid and sustained increase in hemoglobin greater than 3 g/dL, which is above the average (1.48 g/ dL) of that reported in the BEYOND study [8](Figure 1).”
InfluentialSelf-citationAhmad, S., Khan, L., Mustafa, M., Khan, Y., Shah, S. F., Ahmad, F., Khan, T., Zeb, M. A., Zaman, Q., & Jelani, M. (2026) · Thalassemia Reports · doi:10.3390/thalassrep16030014
“The severity of the β -thalassemia depends on the genotype; the β 0 mutation results in severe anemia and requires transfusions, whereas the β + mutation is usually present in a mild clinical form [16].”
Shoaib, R., Maqbool, A., Khan, K., Imtiaz, S. N., Khan, M. T. M., & Rani, G. F. (2026) · Iraqi Journal of Hematology · doi:10.4103/ijh.ijh_23_26
Teawtrakul, N., Sribenjalak, D., Theerakulpisut, D., Charoenngam, N., & Pongchaiyakul, C. (2026) · Hemoglobin · doi:10.1080/03630269.2026.2708953
“Second, therapies that reduce ineffective erythropoiesis, such as luspatercept, which is now approved for adult β-thalassemia [40], may plausibly confer downstream skeletal benefit by reducing the drive for marrow expansion, though this has not been tested.”
Najmi, A. H., Darwish, A. R. A., Alshahrani, A. A., Almalki, T. J., Hassanien, S. S. M., Tawhari, F. H., Abualama, A. E., Ahmed, A. M., Asiri, S. M., Alwadai, A. S., et al. (2026) · Journal Of Advanced Pharmacy Education And Research · doi:10.51847/jsthpjkb4k
Papingiotis, G., Mantzourani, M., Gogas, H., Filippatos, G. S., & Farmakis, D. T. (2026) · Heart Failure Reviews · doi:10.1007/s10741-026-10663-x
Karen, A. A., Tluli, O., Hashem, I. E.-A., Barhoma, A. M., Hamid, M. A., AlQahtani, A. O., Alshurafa, A., Soliman, A. T., Albattah, A., & Yassin, M. A. (2026) · Hemoglobin · doi:10.1080/03630269.2026.2709700
Kadhim, S. J., Khamis, D. A., & Jasim, H. A. (2026) · Folia Medica · doi:10.3897/folmed.68.e177504
Makis, A. C., Saougou, I., & Vlahos, A. P. (2026) · Thalassemia Reports · doi:10.3390/thalassrep16030022
“Luspatercept, a transforming growth factor-β (TGF-β ) superfamily ligand trap, reduces transfusion burden in adults with TDT [78].”
Boccadifuoco, U., Lerner, I., Godard, A., Darnige, L., Joseph, L., Nemer, W. E., Cheminet, G., & Arlet, J. (2026) · American Journal of Hematology · doi:10.1002/ajh.70497
Mitapivat for transfusion-dependent α-thalassaemia and β-thalassaemia
Frangoul, H., & Hussein, A. A. (2026) · The Lancet · doi:10.1016/s0140-6736(26)01609-0
Tonelli, A. R., Aulak, K. S., Berro, J., & Highland, K. B. (2026) · Respiratory Medicine · doi:10.1016/j.rmed.2026.109151
2026 Update on Clinical Trials in β‐Thalassemia
Musallam, K. M., Locatelli, F., Algeri, M., Cappellini, M. D., & Taher, A. T. (2026) · American Journal of Hematology · doi:10.1002/ajh.70472 · Cited by 1
Self-citationFan, H., & Jin, S. (2026) · Frontiers in Chemistry · doi:10.3389/fchem.2026.1917991
“Luspatercept, a related ligand trap approved for transfusion-dependent anemias in β -thalassemia and myelodysplastic syndromes, has secondary effects on bone metabolism that have not been systematically characterized (Cappellini et al., 2020).”
Costa, A. K. F., Faria, J. T. B., Silva, G. V. D. A., Guimarães, R. F. D. C., Grecco, C. E. S., Costa, T. C. D. M., Traina, F., Simões, B. P., & Darrigo, L. G. (2026) · Thalassemia Reports · doi:10.3390/thalassrep16040025
de Montalembert, M., Bevacqua, M., Allali, S., & Brissot, P. (2026) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2026.06.017
Jin, Q., Tian, D., Chen, D., Li, M., Hou, S., Zhang, X., Pan, W., Zhou, D., Guan, L., & Ge, J. (2026) · Pulmonary Circulation · doi:10.1002/pul2.70405
Fernando, K., Perera, S., & Premawardhena, A. (2026) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.70330
Metadata
- Authors
- Cappellini, M. D., Viprakasit, V., Taher, A. T., Georgiev, P., Kuo, K. H. M., Coates, T., Voskaridou, E., Liew, H.-K., Pazgal-Kobrowski, I., Forni, G. L., Perrotta, S., Khelif, A., Lal, A., Kattamis, A., Vlachaki, E., Origa, R., Aydinok, Y., Bejaoui, M., Ho, P. J., Chew, L.-P., Bee, P.-C., Lim, S.-M., Lu, M.-Y., Tantiworawit, A., Ganeva, P., Gercheva, L., Shah, F., Neufeld, E. J., Thompson, A., Laadem, A., Shetty, J. K., Zou, J., Zhang, J., Miteva, D., Zinger, T., Linde, P. G., Sherman, M. L., Hermine, O., Porter, J., & Piga, A.
- Affiliations
- University of Milan (IT)
- Siriraj Hospital (TH)
- University Health Network (CA)
- University of Southern California (US)
- From the Department of Clinical Sciences and Community, University of Milan, IRCCS Ca’ Granda Foundation Maggiore Policlinico Hospital, Milan (M.D.C.), Centro della Microcitemia e Anemie Congenite e del Dismetabolismo del Ferro, E.O. Ospedali Galliera, Genoa (G.L.F.), Ospedale Pediatrico Microcitemico A. Cao, Azienda Ospedaliera G. Brotzu, Cagliari (R.O.), Ematologia e Oncologia Pediatrica, Università della Campania L. Vanvitelli, Caserta (S.P.), and the Department of Clinical and Biological...
- University of California, San Francisco (US)
- The University of Sydney (AU)
- University Malaya Medical Centre (MY)
- St. Jude Children's Research Hospital (US)
- Lurie Children's Hospital (US)
- Hôpital Necker-Enfants Malades (FR)
- University College London Hospitals NHS Foundation Trust (GB)
- ORCID
- Cappellini, M. Domenica
- Viprakasit, Vip
- Taher, Ali T.
- Georgiev, Pencho
- Kuo, Kevin H.M.
- Coates, Thomas
- Voskaridou, Ersi
- Perrotta, Silverio
- Lal, Ashutosh
- Kattamis, Antonis
- Vlachaki, Efthymia
- Origa, Raffaella
- Ho, P. Joy
- Bee, Ping-Chong
- Lu, Meng-Yao
- Tantiworawit, Adisak
- Gercheva, Liana
- Shah, Farrukh
- Neufeld, Ellis J.
- Thompson, Alexis
- Laadem, Abderrahmane
- Shetty, Jeevan K.
- Sherman, Matthew L.
- Hermine, Olivier
- Piga, Antonio
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-03-26
- Volume
- 382
- Issue
- 13
- Pages
- 1219-1231
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3014005795
- Cited by
- 332
- References
- 28
- Citations by year
- 2026: 51 · 2025: 48 · 2024: 57 · 2023: 49 · 2022: 54 · 2021: 52 · 2020: 21
- FWCI
- 22.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- UNICA IRIS Institutional Research Information System (University of Cagliari) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- Funders
- Acceleron Pharma
- Celgene
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Health Sciences › Medicine › Hematology › Blood transfusion and management
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Keywords
- transfusion-dependent beta-thalassemia, transfusion burden, erythroid maturation, recombinant fusion protein, serum ferritin, iron overload, adverse events, hyperuricemia, hypertension, bone pain, joint pain, dizziness, best supportive care
- MeSH terms
- Adolescent, Adult, Aged, Double-Blind Method, Female, Ferritins, Hematinics, Humans, Immunoglobulin Fc Fragments, Male, Middle Aged, Recombinant Fusion Proteins, Splenectomy, Odds Ratio, Least-Squares Analysis, beta-Thalassemia, Erythrocyte Transfusion, Activin Receptors, Type II, Young Adult, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.